MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.


Player Avatar TelsaRowe (46.75) Submitted: 1/10/2013 10:30:16 AM : Outperform Start Price: $2.61 MNKD Score: +97.85

Big pharma has lost several big blockbuster drugs to expiring exclusivity over the past year and will be looking to aquire potential replacements. Mnkd's drug candidate Afrezza fits perfectly bacause of diabetes broad and dramatically increasing population. Upon positive trial news sometime in the middle of 2013 I expect Big Pharma to come in swiftly.

Featured Broker Partners